What do we want? A therapy and a cure! When do we want it? Now! Call-and-response is a tactic often used in protests. Raising many voices together to deliver the same message is a powerful force. Together as a community, we can deliver that message. The Pulmonary Fibrosis Foundation‘s (PFF)…
Targeting ‘overlooked’ gene could lead to new treatments for IPF: Study
Treatment with Esbriet (pirfenidone) reduces the risk of irregular heartbeat by nearly 90% in adults with idiopathic pulmonary fibrosis (IPF), according to a new study. Use of the approved IPF drug also eased the worsening of atrial arrhythmias — irregular heartbeats originating in the upper chambers of the heart —…
How was Stonehenge constructed some 5,500 years ago? How were the stones moved, and who moved them? Why were the monolithic statues erected on Easter Island? Do questions like these weigh on you? I enjoy a good mystery, and my journey with idiopathic pulmonary fibrosis (IPF) has all the…
New Phase 2a clinical trial data suggest that treatment with GRI-0621, an experimental oral therapy from GRI Bio, altered the activity of genes linked to inflammation and lung scarring (fibrosis) in adults with idiopathic pulmonary fibrosis (IPF). The therapy was also associated with increased activity of genes involved…
Note: This column describes the author’s own experiences with Protonix (pantoprazole), Prograf (tacrolimus), Rapamune (sirolimus), and Forteo (teriparatide injection). Not everyone will have the same response to treatment. Consult your doctor before starting or stopping a therapy. Pulmonary fibrosis patients, no matter where they are in their journey, require…
Years before my husband, Donnie, first began having breathing troubles, he suffered from stiff, achy muscles and exhaustion. Each night, he’d come home from work exhausted, sore, and discouraged by the pain his body was experiencing. At first, he attributed his discomfort to residual soreness from working in a high-paced…
Activity levels of four genes linked to the Notch signaling pathway — which helps regulate cell growth, tissue repair, and immune responses in the body — may serve as blood-based biomarkers that could aid in the early diagnosis of idiopathic pulmonary fibrosis (IPF). Those are the findings of a…
I’ve been writing recently about the four pillars of the Pulmonary Fibrosis Foundation’s (PFF) new five-year strategic plan introduced last year, called “The PFF Is ME.” In December, I explained the first pillar, Accelerate Research. The second pillar, Expand Access to Expert Care, is a concern for…
The European Medicines Agency (EMA) has awarded orphan drug designation to Rein Therapeutics’ lead drug candidate, LTI-03, which is being developed to help preserve lung function in people with idiopathic pulmonary fibrosis (IPF). The designation follows a positive opinion from the EMA’s Committee for Orphan Medicinal Products, which evaluates…
